ALFA Finder| Value | ₹11.30 Cr |
|---|
BSE filing, NSE: FREDUN. Summary written from the filing by ALFA Finder's alert engine.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,508.10
- Market cap
- ₹2,161 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 40.8×Sector 43.4×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Q2 FY27 Results: Net Profit ₹18.6 Cr, Up 97.9% YoY
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹265.9 Cr (+85.2% YoY) and net profit of ₹18.6 Cr (+97.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.6 Cr · +97.9% YoY
Fredun Pharmaceuticals Board Meeting Date
Fredun Pharmaceuticals will hold a board meeting on 05 November 2026 to consider half-year results. Trading window stays closed until 48 hours after results.
Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.
Other board meeting outcome announcements
All →Balmer Lawrie Investments Board Meeting Outcome
Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.
- Execution
- FY 2026-27
Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.
BCC Fuba India Board Meeting Outcome
BCC Fuba India's board met on November 6, 2026 and took note of consolidated related party transactions for the half year ended September 30, 2026. No financial results, capital raise or other material decision was reported.
Voltas Board Meeting Outcome
Voltas Limited's board approved Deloitte Haskins & Sells as statutory auditors for five years from the 73rd AGM, replacing SRBC & Co. LLP, whose second and final term ends at that AGM. Subject to shareholder approval.
- Execution
- Five years: financial years 2027-28 to 2031-32 (from the 73rd AGM in 2027 to the 78th AGM in 2032)